CMS has not assumed responsibility for “deduplicating” discounts that arise between the 340B program and the IRA's Medicare drug price negotiations.
CMS Inaction on IRA-340B Conflicts May Drive ‘Manufacturer-Friendly’ Compliance Models
Federal regulators’ inaction on the 340B program’s interactions with Medicare drug price negotiations will likely lead drugmakers to pursue “manufacturer-friendly” [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
